FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors

SYNGENE Consensus Forecast

No. of reports in last year
1
No. of analysts
1
Average Consensus Forecast
635
Consensus Potential
1.15%

SYNGENE Price Target Potential

BrokerageTargetPotential
ICICIdirect.com6351.15%

SYNGENE Targets in FrontPage Forums

2 Users have submitted 2 trade ideas of Rs. 112,624.5 for SYNGENE
100% Bullish
0% Bearish
See buy or sell ideas on FrontPage Forums >>

SYNGENE Ratings

Long term SYNGENE rating by FrontPage users
5/5 (1 Ratings)

1 SYNGENE share price target reports by brokerages below. See what is analyst's view on SYNGENE share price forecast, rating, estimates, valuation and prediction behind the target. You may use these research report forecasts for long-term to medium term for your investment or trades in 2020.
  1. Home
  2. SYNGENE Forum
  3. SYNGENE Price Target

SYNGENE Share Price Target

SYNGENE Share Price Target - Broker Reports - 2020

23-Oct-20
Price @ Call: 533.91
Target: 635
BUY
14-May-20
Price @ Call: 335.5
Target: 390
BUY
Q4 numbers were a significant beat despite Covid 19 related BCP challenges, which validates stickiness of the business in a tough environment. Although the management does expect some impact in Q1FY21 both on topline and profitability, they are guiding double-digit revenues growth on the back of continuous client additions, an extension of existing contracts, increasing manufacturing and biological contributions besides currency tailwinds. Profitability is likely to be muted due to incremental opex and higher depreciation. The company remains aggressive on the capex front (~US$451 million already spent & another ~US$100 million earmarked by FY21), attributable to order book visibility. Asset turnover from this mega capex will be a significant determinant for improvement in return ratios, going ahead. With elite client additions like Amgen, Zoetis, Herbalife, GSK, etc, and multiple year extension of BMS and Baxter contracts, the company remains well poised to capture opportunities in the global CRO space. We arrive at a target price of | 390 based on ~32x FY22 EPS of Rs 12.2
... Read more
24-Jan-20
Price @ Call: 307.51
Target: 360
HOLD
As per the management’s own assertion, revenue growth for 9MFY20 has been behind the guidance curve as the order offtake is yet to gain the expected momentum. That said, the management has guided for decent traction for FY21 mainly due to continuous client additions, extension of existing contracts besides increasing manufacturing and biological contributions. The company remains aggressive on the capex front (~US$425 million already spent + another US$ 125 million earmarked by FY21), attributable to firm growth plans. The asset turnover from this mega capex will be a significant determinant for future visibility. On the margins front, the company is witnessing some pressure due to compliance, safety and quality related expenses besides employee addition, which, we believe, are attributable to increasing scalability and which is likely to persist. The company has recently added some elite clients like Amgen, Zoetis, Herbalife, GSK and multiple year extension of BMS and Baxter contracts. In a nutshell, the company remains well poised to capture opportunities in the global CRO space on account of strategic outsourcing by global innovators. We arrive at a target price of Rs 360 based on ~30x FY22 EPS of Rs 12.0.
... Read more

SYNGENE Share Price Target - Broker Reports - 2019

26-Jul-19
Price @ Call: 308
Target: 360
BUY
The company remains aggressive on the capex front (~US$380 million already spent + another US$170 million earmarked by FY21), which is attributable to firm growth plans and clear visibility. On the margins front, the company is witnessing some pressure due to compliance, safety and quality related expenses besides employee addition. We believe this is attributable to increasing scalability and which is likely to persist. Overall, the company remains well poised to capture opportunities in the global CRO space on account of strategic outsourcing by global innovators. We arrive at a target price of Rs 360 based on ~35x FY21 EPS of Rs 10.3.
... Read more
25-Apr-19
Price @ Call: 305.86
Target: 178.75
BUY
The company remains aggressive on the capex front (US$350 million already spent + another US$200 million earmarked by FY21), due to firm growth plans and clear visibility. On the margins front, the company is witnessing some pressure due to compliance, safety and quality related expenses besides employee addition, which, we believe, are attributable to increasing scalability and that is likely to persist. Overall, the company remains well poised to capture opportunities in the global CRO space on account of strategic outsourcing by global innovators. We arrive at a target price of Rs 715 based on ~35x FY21 EPS of Rs 20.5.
... Read more
28-Jan-19
Price @ Call: 292.53
Target: 163.75
BUY
24-Jan-19
Price @ Call: 286.5
Target: 168.75
BUY

SYNGENE Share Price Target - Broker Reports - 2018

27-Jul-18
Price @ Call: 293.12
Target: 171.25
BUY
29-Jan-18
Price @ Call: 620.7
Target: 680
BUY

SYNGENE Share Price Target - Broker Reports - 2017

11-Sep-17
Price @ Call: 480
Target: 550
BUY
31-Jul-17
Price @ Call: 476
Target: 558
BUY
31-Jul-17
Price @ Call: 483
Target: 490
HOLD
6-Jul-17
Price @ Call: 478
Target: 564
BUY
2-May-17
Price @ Call: 498
Target: 515
HOLD
17-Feb-17
Price @ Call: 492
Target: 565
BUY

SYNGENE Share Price Target - Broker Reports - 2016

28-Apr-16
Price @ Call: 388
Target: 400
HOLD
24-Oct-16
Price @ Call: 547.1
Target: 570
HOLD
7-Sep-16
Price @ Call: 472
Target: 570
BUY
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 2,00,000 Indian traders and discuss trades, strategies, news & views on any stock.
  • SYNGENE Share Price Target Today- Technical Pivot Points (Classic)

    keyboard_arrow_down
    Upside Target 3662.83
    Upside Target 2650.42
    Upside Target 1639.28
    Pivot626.87
    Downside Target 1615.73
    Downside Target 2603.32
    Downside Target 3592.18
  • SYNGENE Share Price Target weekly- Technical Pivot Points (Classic)

    keyboard_arrow_down
    Upside Target 3745.42
    Upside Target 2716.48
    Upside Target 1672.32
    Pivot643.38
    Downside Target 1599.22
    Downside Target 2570.28
    Downside Target 3526.12
  • SYNGENE Share Price Target monthly- Technical Pivot Points (Classic)

    keyboard_arrow_down
    Upside Target 3631.95
    Upside Target 2615.9
    Upside Target 1599.6
    Pivot583.55
    Downside Target 1567.25
    Downside Target 2551.2
    Downside Target 3534.9
  • SYNGENE Share Price Target today- Technical Pivot Points (Fibonacci)

    keyboard_arrow_down
    Upside Target 3650.42
    Upside Target 2641.42
    Upside Target 1635.86
    Pivot626.87
    Downside Target 1617.87
    Downside Target 2612.31
    Downside Target 3603.32
  • SYNGENE Share Price Target weekly- Technical Pivot Points (Fibonacci)

    keyboard_arrow_down
    Upside Target 3716.48
    Upside Target 2688.56
    Upside Target 1671.31
    Pivot643.38
    Downside Target 1615.46
    Downside Target 2598.21
    Downside Target 3570.28
  • SYNGENE Share Price Target monthly- Technical Pivot Points (Fibonacci)

    keyboard_arrow_down
    Upside Target 3615.9
    Upside Target 2603.54
    Upside Target 1595.91
    Pivot583.55
    Downside Target 1571.19
    Downside Target 2563.56
    Downside Target 3551.2
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.
PrivacyTerms
FrontPage © 2020